Pour les chercheurs

La recherche d'aujourd'hui mène aux percées de demain.

Rejoignez notre liste de diffusion pour les nouvelles de l'AFTD Research et les opportunités de financement
Holloway Logo_Final_4-2022_Poppins-Lora-fonts (1) (002)

Sommet Holloway

In 2021, AFTD Board member Kristin Holloway generously established the Fonds de la famille Holloway at AFTD, making the Holloway Summit series possible. Each year, the Summit brings together innovative thought-leaders to focus on a different topic in FTD research. Attendees span academic and industry scientists, non-profit and government funders, experts from related fields, and people with lived experience with FTD.

2023: Biomarkers for FTD

2023 Holloway Summit - Attendees

November 29-December 1 | Miami Beach, FL

Chairs: Danielle Graham, PhD (Biogen), Stacie Weninger, PhD (F-Prime Biomedical Research Initiative), Henrik Zetterberg, PhD (University of Gothenburg)

AFTD Leadership: Penny Dacks, PhD (Senior Director of Scientific Initiatives), Debra Niehoff, PhD (Director of Grants and Research), Amanda Gleixner, PhD (Research Project Manager)

Program: Cliquez ici pour voir

Topics:

  • Data and biosample resources to accelerate biomarker development
  • Current and emergent biomarkers for FTD
  • Biomarker approaches to identify which patients have which causes of FTD
  • Biomarker approaches to improve access to early and accurate diagnosis
  • Biomarker approaches to enable clinical trials for potential treatments

More information on the meeting can be found here: Second Holloway Summit Showcases Intense Search for FTD Biomarkers | ALZFORUM.

2022: Digital Assessment Tools for FTD

Holloway Summit Cover

May 18 - 20 |  Miami, FL

The phrase “digital assessment tools” refers to emerging technologies that allow researchers to use smartphones, wearable trackers, or other devices to remotely measure aspects of a person's health, such as diseases symptoms and function.

Chairs: Naomi Nevler, MD (Université de Pennsylvanie) et Jonathan Rohrer, MD (University College London et Genetic Frontotemporal Dementia Initiative)

AFTD Leadership: Penny Dacks, PhD (directrice principale des initiatives scientifiques) et Debra Niehoff, PhD (directrice des subventions et de la recherche)

Topics:

  • Development of tools to remotely measure the diverse potential symptoms of FTD.
  • How digital assessment tools can reduce travel burden to expand access to clinical trial participation, diagnosis, and care.
  • Roadmap to successful development of digital assessment tools.
  • Overcoming challenges with digital assessment tools development.

More information on the meeting can be found here: Digital Biomarkers of FTD: How to Move from Tech Tinkering to Trials? | ALZFORUM